Johnson & Johnson announced that the UK’s National Institute for Health and Care Excellence (NICE) recommended Rybrevant (amivantamab) in combination with chemotherapy. The guidance applies to adult patients with advanced non-small cell lung cancer (NSCLC) harboring the EGFR exon 20 insertion mutation.
This decision enables the National Health Service (NHS) to offer the treatment through the Cancer Drugs Fund in England and Wales. Patients with this specific mutation typically face poorer prognoses compared to those with other common EGFR mutations.
The positive recommendation marks a significant step for J&J in expanding the availability of this therapy within the United Kingdom. Initial reports showed no immediate market reaction to the announcement.